PAVmed Inc. PAVM
Medical/Dental Instruments · IPO 2016 · data as of November 13, 2026
PAVmed Inc. (PAVM) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $148000 and net income of -$18M, a net margin of -12472.3%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -140%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.
About PAVmed
PAVmed is listed in the US and classified in medical/dental instruments, IPO year 2016. It was profitable in 2 of the last 10 years in our data. Its share count rose by 239% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148000 | — | — | $2M | $377000 | $500000 | — | — | — | — | — |
| Net income | -$18M | $401000 | $40M | -$64M | -$89M | -$50M | -$34M | -$16M | -$18M | -$10M | -$6M |
| Free cash flow | — | -$5M | -$34M | -$52M | -$73M | -$42M | -$22M | -$13M | -$9M | -$7M | -$4M |
| EPS (diluted) | $-7.78 | $-5.63 | $14.90 | $-275.18 | $-451.52 | $-19.53 | $-21.63 | $-16.22 | $-24.33 | $-21.33 | $-13.22 |
| Net margin | -12472.3% | — | — | -2567.0% | -23602.9% | -10069.4% | — | — | — | — | — |
| ROIC | — | -49.5% | -174.5% | — | -267.0% | -69.7% | -840.0% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $36.50, 2139% above the current price; targets range from $16.00 to $57.00; the consensus rating is “none”; expected EPS is $-2.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is PAVmed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does PAVmed pay a dividend?
Not currently.
Is PAVmed a good stock to buy?
We do not give buy or sell advice. PAVmed scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.